The TP53 mutation was also found to be strongly associated with the immune microenvironment in hepatocellular carcinoma (Long et al., 2019), and it can significantly enhance the expression of immune checkpoint-related proteins and serve as a predictor of immunotherapy in lung cancer (Dong et al., 2017). The gene discussed is TP53; the disease is lung cancer.